Be aware that long-term home oxygen therapy may be offered for comorbidities, such as for some people with chronic obstructive pulmonary disease (see section 1.2.5 on oxygen in the NICE guidline on chronic obstructive pulmonary disease in over 16s. [2018] 86.If it is thought that a person may be entering the last 2 to 3 days of life, follow the NICE guideline on care of dying adults in the last days of life. [2018] See NICE s technology appraisal guidance on implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure. 87.When discussing implantation of a cardioverter defibrillator: explain the risks, benefits and consequences of cardioverter defibrillator implantation, following the principles on shared decision making in the NICE guideline on patient experience in adult NHS services ensure the person knows that the defibrillator can be deactivated without affecting any cardiac resynchronisation or pacing, and reactivated later explain the circumstances in which deactivation might be offered discuss and dispel common misconceptions about the function of the device and the consequences of deactivation provide the person and, if they wish, their family or carers with written information covering the information discussed. [2018] 88.Review the benefits and potential harms of a cardioverter defibrillator remaining active in a person with heart failure: at each 6-monthly review of their heart failure care whenever their care goals change as part of advance care planning if it is thought they are nearing the end of life. [2018] 89.Do not use prognostic risk tools to determine whether to refer a person with heart failure to palliative care services. [2018] 90.If the symptoms of a person with heart failure are worsening despite optimal specialist treatment, discuss their palliative care needs with the specialist heart failure MDT and consider a needs assessment for palliative care. [2018] 91.People with heart failure and their families or carers should have access to professionals with palliative care skills within the heart failure team. [2003] Chronic Heart Failure Reference list NICE 2018. All rights reserved. Subject to Notice of rights. ISBN: 978-1-4731-3093-7 11 Reference list 1. Abhayaratna WP, Marwick TH, Becker NG, Jeffery IM, McGill DA, Smith WT. Population- based detection of systolic and diastolic dysfunction with amino-terminal pro-B-type natriuretic peptide. American Heart Journal. 2006; 152(5):941-948 2. Ademi Z, Pasupathi K, Krum H, Liew D. Cost effectiveness of eplerenone in patients with chronic heart failure. American Journal of Cardiovascular Drugs. 2014; 14(3):209-16 3. Ademi Z, Pasupathi K, Liew D. Cost-effectiveness of eplerenone compared to usual care in patients with chronic heart failure and NYHA class ii symptoms, an Australian perspective. 4. Adlbrecht C, Huelsmann M, Berger R, Moertl D, Strunk G, Oesterle A et al. Cost analysis and cost-effectiveness of NT-proBNP-guided heart failure specialist care in addition to home- based nurse care. European Journal of Clinical Investigation. 2011; 41(3):315-22 5. Agostoni P, Magini A, Andreini D, Contini M, Apostolo A, Bussotti M et al. Spironolactone improves lung diffusion in chronic heart failure. European Heart Journal. 2005; 26(2):159-164 6. Agvall B, Alehagen U, Dahlstrom U. The benefits of using a heart failure management programme in Swedish primary healthcare. European Journal of Heart Failure. 2013; 7. Al-Sutari MM, Ahmad MM. Effect of educational program on self-care behaviors and health outcome among patients with heart failure: an experimental study. International Journal of Evidence Based Healthcare. 2017; 15(4):178-185 8. Aldred H, Gott M, Gariballa S. Advanced heart failure: impact on older patients and informal carers. Journal of Advanced Nursing. 2005; 49(2):116-24 9. All Party Parliamentary Group on Heart Disease. Focus on heart failure: 10 recommendations to improve care and transform lives. London. British Heart Foundation, 2016. 10. Allen LA, Matlock DD, Shetterly SM, Xu S, Levy WC, Portalupi LB et al. Use of risk models to predict death in the next year among individual ambulatory patients with heart failure. JAMA 11. Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduganathan M et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. Journal of the American College of Cardiology. 2014; 12. Anand IS, Bishu K, Rector TS, Ishani A, Kuskowski MA, Cohn JN. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin- converting enzyme inhibitor in patients with moderate to severe heart failure Circulation. 13. Anderson L, Sharp GA, Norton RJ, Dalal H, Dean SG, Jolly K et al. Home-based versus centre- based cardiac rehabilitation. Cochrane Database of Systematic Reviews 2017, Issue Art. No.: CD007130. DOI: 10.1002/14651858.CD007130.pub4. 14. Andersson L, Eriksson H, Nordgren L. Differences between heart failure clinics and primary health care. British Journal of Community Nursing. 2013; 18(6):288-92 15. Angermann CE, Stork S, Gelbrich G, Faller H, Jahns R, Frantz S et al. Mode of action and effects of standardized collaborative disease management on mortality and morbidity in Chronic Heart Failure Reference list NICE 2018. All rights reserved. Subject to Notice of rights. ISBN: 978-1-4731-3093-7 patients with systolic heart failure the interdisciplinary network for heart failure (INH) study. Circulation: Heart Failure. 2012; 5(1):25-35 16. Anguita M, Esteban F, Castillo JC, Mazuelos F, Lopez-Granados A, Arizon JM et al. [Usefulness of brain natriuretic peptide levels, as compared with usual clinical control, for the treatment monitoring of patients with heart failure]. Medicina Cl nica. 2010; 135(10):435-40 17. Anker SD, Colet JC, Filippatos G, Willenheimer R, Dickstein K, Drexler H et al. Rationale and design of Ferinject assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia. European Journal of Heart Failure. 18. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. New England Journal of 19. Antonicelli R, Testarmata P, Spazzafumo L, Gagliardi C, Bilo G, Valentini M et al. Impact of telemonitoring at home on the management of elderly patients with congestive heart failure. Journal of Telemedicine and Telecare. 2008; 14(6):300-5 20. Askoxylakis V, Thieke C, Pleger ST, Most P, Tanner J, Lindel K et al. Long-term survival of cancer patients compared to heart failure and stroke: a systematic review. BMC Cancer. 21. Athanasakis K, Bilitou A, Lee D, Karampli E, Karavidas A, Parissis J et al. Cost-effectiveness of eplerenone in NYHA class II chronic heart failure patients with reduced LVEF: an analysis for Greece. Clinicoeconomics & Outcomes Research. 2016; 8:583-590 22. Atienza F, Anguita M, Martinez-Alzamora N, Osca J, Ojeda S, Almenar L et al. Multicenter randomized trial of a comprehensive hospital discharge and outpatient heart failure management program. European Journal of Heart Failure. 2004; 6(5):643-652 23. Baker DW, Dewalt DA, Schillinger D, Hawk V, Ruo B, Bibbins-Domingo K et al. The effect of progressive, reinforcing telephone education and counseling versus brief educational intervention on knowledge, self-care behaviors and heart failure symptoms. Journal of 24. Baker DW, Jones R, Hodges J, Massie BM, Konstam MA, Rose EA. Management of heart failure. III. The role of revascularization in the treatment of patients with moderate or severe left ventricular systolic dysfunction. Journal of the American Medical Association. 1994; 25. Balk AH, Davidse W, Dommelen P, Klaassen E, Caliskan K, van der Burgh P et al. Tele-guidance of chronic heart failure patients enhances knowledge about the disease. A multi-centre, randomised controlled study. European Journal of Heart Failure. 2008; 10(11):1136-42 26. Barnes S, Gott M, Payne S, Seamark D, Parker C, Gariballa S et al. Communication in heart failure: perspectives from older people and primary care professionals. Health & Social Care in the Community. 2006; 14(6):482-90 27. Barr CS, Lang CC. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. American Journal of Cardiology. 1995; 76(17):1259-1265 28. Barth V. A nurse-managed discharge program for congestive heart failure patients: Outcomes and costs. Home Health Care Management & Practice. 2001; 13(6):436-443 Chronic Heart Failure Reference list NICE 2018. All rights reserved. Subject to Notice of rights. ISBN: 978-1-4731-3093-7 29. Baudendistel I, Noest S, Peters-Klimm F, Herzberg H, Scherer M, Blozik E et al. Bridging the gap between patient needs and quality indicators: a qualitative study with chronic heart failure patients. Patient Preference & Adherence. 2015; 9:1397-405 30. Beck-da-Silva L, de Bold A, Fraser M, Williams K, Haddad H. BNP-guided therapy not better than expert's clinical assessment for beta-blocker titration in patients with heart failure. Congestive Heart Failure. 2005; 11(5):248-253 31. Beck-da-Silva L, Piardi D, Soder S, Rohde LE, Pereira-Barretto AC, de Albuquerque D et al. IRON-HF study: a randomized trial to assess the effects of iron in heart failure patients with anemia. International Journal of Cardiology. 2013; 168(4):3439-42 32. Beck-da-Silva L, Rohde LE, Pereira-Barretto AC, de Albuquerque D, Bocchi E, Vilas-Boas F et al. Rationale and design of the IRON-HF study: a randomized trial to assess the effects of iron supplementation in heart failure patients with anemia. Journal of Cardiac Failure. 2007; 33. Bento VF, Brofman PR. Impact of the nursing consultation on the frequency of hospitalizations in patients with heart failure in Curitiba, Parana State. Arquivos Brasileiros 34. Berger R, Moertl D, Peter S, Ahmadi R, Huelsmann M, Yamuti S et al. N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study. Journal of the American College of Cardiology. 2010; 55(7):645-53 35. Berry C, Murdoch DR, McMurray JJ. Economics of chronic heart failure. European Journal of 36. Beta-Blocker Evaluation of Survival Trial Investigators, Eichhorn EJ, Domanski MJ, Krause- Steinrauf H, Bristow MR, Lavori PW. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. New England Journal of Medicine. 2001; 344(22):1659-67 37. Bhardwaj A, Rehman SU, Mohammed A, Baggish AL, Moore SA, Januzzi JL, Jr. Design and methods of the Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study. American Heart Journal. 2010; 159(4):532-538.e1 38. Bhardwaj A, Rehman SU, Mohammed AA, Gaggin HK, Barajas L, Barajas J et al. Quality of life and chronic heart failure therapy guided by natriuretic peptides: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study. American Heart Journal. 39. Bhopal RS, Bansal N, Fischbacher CM, Brown H, Capewell S. Ethnic variations in heart failure: Scottish Health and Ethnicity Linkage Study (SHELS). Heart. 2012; 98(6):468-73 40. Biannic C, Coutance G, Calus J, Belin A. Educational home follow-up by telemedicine in cases of cardiac insufficiency. Randomised, multicentric study from the Basse-Normandie region. Preliminary results. European Research in Telemedicine. 2012; 1(1):40-48 41. Blum K, Gottlieb SS. The effect of a randomized trial of home telemonitoring on medical costs, 30-day readmissions, mortality, and health-related quality of life in a cohort of community-dwelling heart failure patients. Journal of Cardiac Failure. 2014; 20(7):513-21 42. Bohm M, Pogue J, Kindermann I, Poss J, Koon T, Yusuf S. Effect of comorbidities on outcomes and angiotensin converting enzyme inhibitor effects in patients with predominantly left ventricular dysfunction and heart failure. European Journal of Heart Failure. 2014; 16(3):325- Chronic Heart Failure Reference list NICE 2018. All rights reserved. Subject to Notice of rights. ISBN: 978-1-4731-3093-7 43. Bollano E, T ng MS, Hjalmarson A, Waagstein F, Andersson B. Randomised, placebo- controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group. Lancet. 1997; 44. Bonow RO, Castelvecchio S, Panza JA, Berman DS, Velazquez EJ, Michler RE et al. Severity of remodeling, myocardial viability, and survival in ischemic LV dysfunction after surgical revascularization. JACC: Cardiovascular Imaging. 2015; 8(10):1121-9 45. Bottle A, Goudie R, Bell D, Aylin P, Cowie MR. Use of hospital services by age and comorbidity after an index heart failure admission in England: an observational study. BMJ Open. 2016; 46. Bowling CB, Sanders PW, Allman RM, Rogers WJ, Patel K, Aban IB et al. Effects of enalapril in systolic heart failure patients with and without chronic kidney disease: insights from the SOLVD Treatment trial. International Journal of Cardiology. 2013; 167(1):151-6 47. Boyd KJ, Murray SA, Kendall M, Worth A, Frederick Benton T, Clausen H. Living with advanced heart failure: A prospective, community based study of patients and their carers. European Journal of Heart Failure. 2004; 6(5):585-591 48. Brandon AF, Schuessler JB, Ellison KJ, Lazenby RB. The effects of an advanced practice nurse led telephone intervention on outcomes of patients with heart failure. Applied Nursing 49. Brannstrom M, Boman K. A new model for integrated heart failure and palliative advanced homecare rationale and design of a prospective randomized study. European Journal of 50. Brannstrom M, Boman K. Effects of person-centred and integrated chronic heart failure and palliative home care. PREFER: a randomized controlled study. European Journal of Heart 51. Br nnstr m M, Forssell A, Pettersson B. Physicians' experiences of palliative care for heart failure patients. European Journal of Cardiovascular Nursing. 2011; 10(1):64-69 52. British Heart Foundation. The national audit of cardiac rehabilitation: annual statistical report 2015. British Heart Foundation, 2015. Available from: https://www.bhf.org.uk/publications/statistics/national-audit-of-cardiac-rehabilitation- 53. Browne S, Macdonald S, May CR, Macleod U, Mair FS. Patient, carer and professional perspectives on barriers and facilitators to quality care in advanced heart failure. PloS One. 54. Brunner-La Rocca HP, Buser PT, Schindler R, Bernheim A, Rickenbacher P, Pfisterer M et al. Management of elderly patients with congestive heart failure design of the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF). American Heart Journal. 2006; 151(5):949-55 55. Brunner-La Rocca HP, Eurlings L, Richards AM, Januzzi JL, Pfisterer ME, Dahlstrom U et al. Which heart failure patients profit from natriuretic peptide guided therapy? A meta-analysis from individual patient data of randomized trials. European Journal of Heart Failure. 2015; 56. Capomolla S, Febo O, Ceresa M, Caporotondi A, Guazzotti G, La Rovere M et al. Cost/utility ratio in chronic heart failure: comparison between heart failure management program Chronic Heart Failure Reference list NICE 2018. All rights reserved. Subject to Notice of rights. ISBN: 978-1-4731-3093-7 delivered by day-hospital and usual care. Journal of the American College of Cardiology. 57. Capomolla S, Pinna G, La Rovere MT, Maestri R, Ceresa M, Ferrari M et al. Heart failure case disease management program: a pilot study of home telemonitoring versus usual care. European Heart Journal Supplements. 2004; 6(Suppl_F):F91-F98 58. Carnethon MR, Pu J, Howard G, Albert MA, Anderson CAM, Bertoni AG et al. Cardiovascular Health in African Americans: A Scientific Statement From the American Heart Association. 59. Carson P, Wertheimer J, Miller A, O'Connor CM, Pina IL, Selzman C et al. The STICH trial (Surgical Treatment for Ischemic Heart Failure): mode-of-death results. JACC Heart Failure. 60. Castagno D, Jhund PS, McMurray JJ, Lewsey JD, Erdmann E, Zannad F et al. Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS-II) trial. European Journal of Heart Failure. 2010; 61. Chaudhry SI, Mattera JA, Curtis JP, Spertus JA, Herrin J, Lin Z et al. Telemonitoring in patients with heart failure. New England Journal of Medicine. 2010; 363(24):2301-9 62. Cheang MH, Rose G, Cheung CC, Thomas M. Current challenges in palliative care provision for heart failure in the UK: a survey on the perspectives of palliative care professionals. Open 63. Clark AL, Johnson M, Fairhurst C, Torgerson D, Cockayne S, Rodgers S et al. Does home oxygen therapy (HOT) in addition to standard care reduce disease severity and improve symptoms in people with chronic heart failure? A randomised trial of home oxygen therapy for patients with chronic heart failure. Health Technology Assessment. 2015; 19(75) 64. Cleland JG, Armstrong P, Horowitz JD, Massie B, Packer M, Poole-Wilson PA et al. Baseline clinical characteristics of patients recruited into the assessment of treatment with lisinopril and survival study. European Journal of Heart Failure. 1999; 1(1):73-9 65. Cleland JG, Calvert M, Freemantle N, Arrow Y, Ball SG, Bonser RS et al. The Heart Failure Revascularisation Trial (HEART). European Journal of Heart Failure. 2011; 13(2):227-33 66. Cleland JG, Louis AA, Rigby AS, Janssens U, Balk AH. Noninvasive home telemonitoring for patients with heart failure at high risk of recurrent admission and death: the Trans-European Network-Home-Care Management System (TEN-HMS) study. Journal of the American College 67. Cohen-Solal A, Kotecha D, van Veldhuisen DJ, Babalis D, Bohm M, Coats AJ et al. Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial. European Journal of Heart Failure. 2009; 11(9):872-80 68. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. New England Journal of Medicine. 2001; 345(23):1667-1675 69. Cohn JN, Tognoni G, Glazer RD, Spormann D, Hester A. Rationale and design of the Valsartan Heart Failure Trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure. Journal of Cardiac Failure. 1999; 5(2):155-60 Chronic Heart Failure Reference list NICE 2018. All rights reserved. Subject to Notice of rights. ISBN: 978-1-4731-3093-7 70. Colin-Ramirez E, McAlister FA, Zheng Y, Sharma S, Armstrong PW, Ezekowitz JA. The long- term effects of dietary sodium restriction on clinical outcomes in patients with heart failure. The SODIUM-HF (Study of Dietary Intervention Under 100 mmol in Heart Failure): a pilot study. American Heart Journal. 2015; 169(2):274-281.e1 71. Collier TJ, Pocock SJ, McMurray JJ, Zannad F, Krum H, van Veldhuisen DJ et al. The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trial. European Heart Journal. 2013; 34(36):2823-9 72. Comin-Colet J, Lainscak M, Dickstein K, Filippatos GS, Johnson P, Luscher TF et al. The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study. European Heart Journal. 73. Comin-Colet J, Rubio-Rodriguez D, Rubio-Terres C, Enjuanes-Grau C, Gutzwiller FS, Anker SD et al. A cost-effectiveness analysis of ferric carboxymaltose in patients with iron deficiency and chronic heart failure in Spain. Revista Espa ola de Cardiolog a. 2015; 68(10):846-51 74. Conrad N, Judge A, Tran J, Mohseni H, Hedgecott D, Crespillo AP et al. Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. Lancet. 75. Coronary artery surgery study (CASS): a randomized trial of coronary artery bypass surgery. Survival data. Circulation. 1983; 68(5):939-950 76. Cowie A, Moseley O. Home- versus hospital-based exercise training in heart failure: an economic analysis. British Journal of Cardiology. 2014; 21:76 77. Cowie A, Thow MK, Granat MH, Mitchell SL. A comparison of home and hospital-based exercise training in heart failure: immediate and long-term effects upon physical activity level. European Journal of Cardiovascular Prevention and Rehabilitation. 2011; 18(2):158-66 78. Cowie A, Thow MK, Granat MH, Mitchell SL. Effects of home versus hospital-based exercise training in chronic heart failure. International Journal of Cardiology. 2012; 158(2):296-8 79. Cowie MR, Struthers AD, Wood DA, Coats AJ, Thompson SG, Poole-Wilson PA et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. 80. Curtis L, Burns A. Unit costs of health & social care 2015. Canterbury. Personal Social Services Research Unit University of Kent, 2015. Available from: http://www.pssru.ac.uk/project- 81. Dang S, Karanam C, Gomez-Marin O. Outcomes of a Mobile Phone Intervention for Heart Failure in a Minority County Hospital Population. Telemedicine Journal & E Health. 2017; 82. Dansky KH, Vasey J, Bowles K. Impact of telehealth on clinical outcomes in patients with heart failure. Clinical Nursing Research. 2008; 17(3):182-199 83. Dar O, Riley J, Chapman C, Dubrey SW, Morris S, Rosen SD et al. A randomized trial of home telemonitoring in a typical elderly heart failure population in North West London: results of the Home-HF study. European Journal of Heart Failure. 2009; 11(3):319-325 84. Dargie H, Lechat P. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Chronic Heart Failure Reference list NICE 2018. All rights reserved. Subject to Notice of rights. ISBN: 978-1-4731-3093-7 85. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left- ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001; 357(9266):1385-90 86. Daskapan A, Arikan H, Caglar N, Tunali N, Ataman S. Comparison of supervised exercise training and home-based exercise training in chronic heart failure. Saudi Medical Journal. 87. de la Porte PW, Lok DJ, van Veldhuisen DJ, van Wijngaarden J, Cornel JH, Zuithoff NP et al. Added value of a physician-and-nurse-directed heart failure clinic: results from the Deventer- Alkmaar heart failure study. Heart. 2007; 93(7):819-25 88. de Lusignan S, Wells S, Johnson P, Meredith K, Leatham E. Compliance and effectiveness of 1 year's home telemonitoring. The report of a pilot study of patients with chronic heart failure. European Journal of Heart Failure. 2001; 3(6):723-30 89. DeBusk RF, Miller NH, Parker KM, Bandura A, Kraemer HC, Cher DJ et al. Care management for low-risk patients with heart failure: a randomized, controlled trial. Annals of Internal 90. Del Sindaco D, Pulignano G, Di Lenarda A, Tarantini L, Cioffi G, Tolone S et al. Role of a multidisciplinary program in improving outcomes in cognitively impaired heart failure older patients. Monaldi Archives for Chest Disease. 2012; 78(1):20-8 91. Del Sindaco D, Pulignano G, Minardi G, Apostoli A, Guerrieri L, Rotoloni M et al. Two-year outcome of a prospective, controlled study of a disease management programme for elderly patients with heart failure. Journal of Cardiovascular Medicine. 2007; 8(5):324-9 92. Dendale P, De Keulenaer G, Troisfontaines P, Weytjens C, Mullens W, Elegeert I et al. Effect of a telemonitoring-facilitated collaboration between general practitioner and heart failure clinic on mortality and rehospitalization rates in severe heart failure: the TEMA-HF 1 (TElemonitoring in the MAnagement of Heart Failure) study. European Journal of Heart 93. Department of Health. NHS reference costs 2015-16. 2016. Available from: accessed: 24/01/2018. 94. Desai AS, Lewis EF, Li R, Solomon SD, Assmann SF, Boineau R et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. American Heart Journal. 2011; 162(6):966-972.e10 95. Desai AS, Swedberg K, McMurray JJ, Granger CB, Yusuf S, Young JB et al. Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program. Journal of the American College of Cardiology. 2007; 50(20):1959-66 96. DeWalt DA, Malone RM, Bryant ME, Kosnar MC, Corr KE, Rothman RL et al. A heart failure self-management program for patients of all literacy levels: a randomized, controlled trial 97. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. New England Journal of Medicine. 1997; 336(8):525-33 98. Doenst T, Cleland JG, Rouleau JL, She L, Wos S, Ohman EM et al. Influence of crossover on mortality in a randomized study of revascularization in patients with systolic heart failure and coronary artery disease. Circulation: Heart Failure. 2013; 6(3):443-50 Chronic Heart Failure Reference list NICE 2018. All rights reserved. Subject to Notice of rights. ISBN: 978-1-4731-3093-7 99. Domanski M, Coady S, Fleg J, Tian X, Sachdev V. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and 100. Domingues FB, Clausell N, Aliti GB, Dominguez DR, Rabelo ER. Education and telephone monitoring by nurses of patients with heart failure: randomized clinical trial. Arquivos Brasileiros de Cardiologia. 2011; 96(3):233-9 101. Dong SJ, de las FL, Brown AL, Waggoner AD, Ewald GA, Davila RV. N-terminal pro B-type natriuretic peptide levels: correlation with echocardiographically determined left ventricular diastolic function in an ambulatory cohort. Journal of the American Society of 102. Doos L, Bradley E, Rushton CA, Satchithananda D, Davies SJ, Kadam UT. Heart failure and chronic obstructive pulmonary disease multimorbidity at hospital discharge transition: a study of patient and carer experience. Health Expectations. 2015; 18(6):2401-2412 103. Doughty RN, Wright SP, Pearl A, Walsh HJ, Muncaster S, Whalley GA et al. Randomized, controlled trial of integrated heart failure management: The Auckland Heart Failure Management Study. European Heart Journal. 2002; 23(2):139-46 104. Doukky R, Avery E, Mangla A, Collado FM, Ibrahim Z, Poulin MF et al. Impact of Dietary Sodium Restriction on Heart Failure Outcomes. JACC Heart Fail. 2016; 4(1):24-35 105. Driscoll A, Srivastava P, Toia D, Gibcus J, Hare DL. A nurse-led up-titration clinic improves chronic heart failure optimization of beta-adrenergic receptor blocking therapy a randomized controlled trial. BMC Research Notes. 2014; 7:668 106. Ducharme A, Doyon O, White M, Rouleau JL, Brophy JM. Impact of care at a multidisciplinary congestive heart failure clinic: a randomized trial. CMAJ: Canadian Medical Association 107. Duerden M, Tabberer M. A budget impact model for a drug in heart failure: Eplerenone. British Journal of Cardiology. 2008; 15(2):101-105 108. Edelmann F, Schmidt AG, Gelbrich G, Binder L, Herrmann-Lingen C, Halle M et al. Rationale and design of the 'aldosterone receptor blockade in diastolic heart failure' trial: a double- blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF). European Journal of Heart Failure. 2010; 12(8):874-82 109. Edelmann F, Wachter R, Schmidt AG, Kraigher-Krainer E, Colantonio C, Kamke W et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: The Aldo-DHF randomized controlled trial. JAMA. 2013; 110. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). American Journal of Cardiology. 1996; 78(8):902-907 111. Ekman I, Andersson B, Ehnfors M, Matejka G, Persson B, Fagerberg B. Feasibility of a nurse- monitored, outpatient-care programme for elderly patients with moderate-to-severe, chronic heart failure. European Heart Journal. 1998; 19(8):1254-60 112. Ekman I, Fagerberg B, Andersson B, Matejka G, Persson B. Can treatment with angiotensin- converting enzyme inhibitors in elderly patients with moderate to severe chronic heart Chronic Heart Failure Reference list NICE 2018. All rights reserved. Subject to Notice of rights. ISBN: 978-1-4731-3093-7 failure be improved by a nurse-monitored structured care program? A randomized controlled trial. Heart and Lung: Journal of Acute and Critical Care. 2003; 32(1):3-9 113. Eschalier R, McMurray JJ, Swedberg K, van Veldhuisen DJ, Krum H, Pocock SJ et al. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). Journal of the American College of 114. Eurlings LW, van Pol PE, Kok WE, van Wijk S, Lodewijks-van der Bolt C, Balk AH et al. Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study. Journal of the American College of Cardiology. 2010; 56(25):2090-100 115. Feldman AM, Mann DL, She L, Bristow MR, Maisel AS, McNamara DM et al. Prognostic significance of biomarkers in predicting outcome in patients with coronary artery disease and left ventricular dysfunction: results of the biomarker substudy of the Surgical Treatment for Ischemic Heart Failure trials. Circulation: Heart Failure. 2013; 6(3):461-72 116. Felker GM, Anstrom KJ, Adams KF, Ezekowitz JA, Fiuzat M, Houston-Miller N et al. Effect of natriuretic peptide-guided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction: A randomized clinical trial. JAMA. 117. Field K, Ziebland S, McPherson A, Lehman R. 'Can I come off the tablets now?'A qualitative analysis of heart failure patients' understanding of their medication. Family Practice. 2006; 118. Filippatos G, Farmakis D, Colet JC, Dickstein K, Luscher TF, Willenheimer R et al. Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial. European Journal of Heart Failure. 2013; 119. Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). European Heart Journal. 120. Fluur C, Bolse K, Str mberg A, Thyl n I. Patients' experiences of the implantable cardioverter defibrillator (ICD); with a focus on battery replacement and end-of-life issues. Heart and 121. Fluur C, Bolse K, Str mberg A, Thyl n I. Spouses' reflections on implantable cardioverter defibrillator treatment with focus on the future and the end-of-life: a qualitative content analysis. Journal of Advanced Nursing. 2014; 70(8):1758-1769 122. Frankenstein L, Goode K, Ingle L, Remppis A, Schellberg D, Nelles M et al. Derivation and validation of a simple clinical risk-model in heart failure based on 6 minute walk test performance and NT-proBNP status do we need specificity for sex and beta-blockers? International Journal of Cardiology. 2011; 147(1):74-8 123. Fry M, McLachlan S, Purdy S, Sanders T, Kadam UT, Chew-Graham CA. The implications of living with heart failure; the impact on everyday life, family support, co-morbidities and access to healthcare: a secondary qualitative analysis. BMC Family Practice. 2016; 17(1):139 Chronic Heart Failure Reference list NICE 2018. All rights reserved. Subject to Notice of rights. ISBN: 978-1-4731-3093-7 124. Fuat A, Hungin P, Murphy JJ. The diagnosis and management of heart failure across primary- secondary care: a qualitative study. British Journal of Cardiology. 2005; 12(3):233-238 125. Galbreath AD, Krasuski RA, Smith B, Stajduhar KC, Kwan MD, Ellis R et al. Long-term healthcare and cost outcomes of disease management in a large, randomized, community- based population with heart failure. Circulation. 2004; 110(23):3518-26 126. Gallacher K, May CR, Montori VM, Mair FS. Understanding patients' experiences of treatment burden in chronic heart failure using normalization process theory. Annals of Family 127. Gastelurrutia P, Gastelurrutia MA, Faus MJ, Bayes-Genis A. Common health problems management uncertainties in heart failure: a qualitative study. Farmacia Hospitalaria. 2012; 128. Gattis WA, Hasselblad V, Whellan DJ, O'Connor CM. Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team: results of the Pharmacist in Heart Failure Assessment Recommendation and Monitoring (PHARM) Study. Archives of Internal Medicine. 1999; 159(16):1939-45 129. Gesica Investigators. Randomised trial of telephone intervention in chronic heart failure: DIAL trial. BMJ. 2005; 331(7514):425 130. Ghali JK, Wikstrand J, Van Veldhuisen DJ, Fagerberg B, Goldstein S, Hjalmarson A et al. The influence of renal function on clinical outcome and response to beta-blockade in systolic heart failure: insights from Metoprolol CR/XL Randomized Intervention Trial in Chronic HF (MERIT-HF). Journal of Cardiac Failure. 2009; 15(4):310-8 131. Giordano A, Scalvini S, Zanelli E, Corra U, Longobardi GL, Ricci VA et al. Multicenter randomised trial on home-based telemanagement to prevent hospital readmission of patients with chronic heart failure. International Journal of Cardiology. 2009; 131(2):192-199 132. Girerd N, Collier T, Pocock S, Krum H, McMurray JJ, Swedberg K et al. Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial. European Heart Journal. 2015; 133. Glogowska M, Simmonds R, McLachlan S, Cramer H, Sanders T, Johnson R et al. Managing patients with heart failure: A qualitative study of multidisciplinary teams with specialist heart failure nurses. Annals of Family Medicine. 2015; 13(5):466-471 134. Goldberg LR, Piette JD, Walsh MN, Frank TA, Jaski BE, Smith AL et al. Randomized trial of a daily electronic home monitoring system in patients with advanced heart failure: the Weight Monitoring in Heart Failure (WHARF) trial. American Heart Journal. 2003; 146(4):705-712 135. Goldstein NE, Mehta D, Siddiqui S, Teitelbaum E, Zeidman J, Singson M et al. "That's like an act of suicide" patients' attitudes toward deactivation of implantable defibrillators. Journal of 136. Goldstein NE, Mehta D, Teitelbaum E, Bradley EH, Morrison RS. "It's like crossing a bridge" complexities preventing physicians from discussing deactivation of implantable defibrillators at the end of life. Journal of General Internal Medicine. 2008; 23 (Suppl 1):2-6 137. Gonzalez-Guerrero JL, Alonso-Fernandez T, Garcia-Mayolin N, Gusi N, Ribera-Casado JM. Effectiveness of a follow-up program for elderly heart failure patients after hospital discharge. A randomized controlled trial. European Geriatric Medicine. 2014; 5(4):252-7 Chronic Heart Failure Reference list NICE 2018. All rights reserved. Subject to Notice of rights. ISBN: 978-1-4731-3093-7 138. GRADE Working Group. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group website. 2011. Available from: http://www.gradeworkinggroup.org/ Last accessed: 12/01/18. 139. Gutzwiller FS, Pfeil AM, Comin-Colet J, Ponikowski P, Filippatos G, Mori C et al. Determinants of quality of life of patients with heart failure and iron deficiency treated with ferric carboxymaltose: FAIR-HF sub-analysis. International Journal of Cardiology. 2013; 140. Gutzwiller FS, Schwenkglenks M, Blank PR, Braunhofer PG, Mori C, Szucs TD et al. Health economic assessment of ferric carboxymaltose in patients with iron deficiency and chronic heart failure based on the FAIR-HF trial: an analysis for the UK. European Journal of Heart 141. Harding R, Selman L, Beynon T, Hodson F, Coady E, Read C et al. Meeting the communication and information needs of chronic heart failure patients. Journal of Pain and Symptom 142. Hardinge M, Annandale J, Bourne S, Cooper B, Evans A, Freeman D et al. British Thoracic Society guidelines for home oxygen use in adults. Thorax. 2015; 70 Suppl 1:i1-43 143. Health and Social Care Information Centre. Prescription cost analysis, England - 2016. 2016. Available from: https://www.nhsbsa.nhs.uk/prescription-data/dispensing-data/prescription- cost-analysis-pca-data Last accessed: 22/01/18. 144. Heckman GA, Boscart VM, McKelvie RS, D Elia T, Osman O, Kaasalainen S et al. Perspectives of primary-care providers on heart failure in long-term care homes. Canadian Journal on 145. Hettwer S, Panzner GB, Witthaut R, Werdan K. Isolated diastolic dysfunction diagnostic value of tissue Doppler imaging, colour M-mode and N-terminal pro B-type natriuretic peptide. Clinical Research in Cardiology. 2007; 96(12):874-882 146. Hobbs FD, Kenkre JE, Roalfe AK, Davis RC, Hare R, Davies MK. Impact of heart failure and left ventricular systolic dysfunction on quality of life: a cross-sectional study comparing common chronic cardiac and medical disorders and a representative adult population. European Heart 147. Hofmarcher T, Borg S. Cost-effectiveness analysis of ferric carboxymaltose in iron-deficient patients with chronic heart failure in Sweden. Journal of Medical Economics. 2015; 148. Horne G, Payne S. Removing the boundaries: palliative care for patients with heart failure. 149. Horneffer PJ, Gardner TJ, Manolio TA, Hoff SJ, Rykiel MF, Pearson TA et al. The effects of age on outcome after coronary bypass surgery. Circulation. 1987; 76(5 Pt 2):V6-12 150. Hsu JJ, Ziaeian B, Fonarow GC. Heart Failure With Mid-Range (Borderline) Ejection Fraction: Clinical Implications and Future Directions. JACC Heart Fail. 2017; 5(11):763-771 151. Hwang R, Bruning J, Morris NR, Mandrusiak A, Russell T. Home-based telerehabilitation is not inferior to a centre-based program in patients with chronic heart failure: a randomised trial. Journal of Physiotherapy. 2017; 63(2):101-107 152. Ibrahim NE, Gaggin HK, Rabideau DJ, Gandhi PU, Mallick A, Januzzi JL, Jr. Worsening renal function during management for chronic heart failure with reduced ejection fraction: Results Chronic Heart Failure Reference list NICE 2018. All rights reserved. Subject to Notice of rights. ISBN: 978-1-4731-3093-7 from the pro-bnp outpatient tailored chronic heart failure therapy (PROTECT) study. Journal of Cardiac Failure. 2017; 23(2):121-130 153. Inglis SC, Clark RA, Dierckx R, Prieto-Merino D, Cleland JG. Structured telephone support or non-invasive telemonitoring for patients with heart failure. Cochrane Database of Systematic Reviews 2015, Issue 10. Art. No.: CD007228. DOI: 10.1002/14651858.CD007228.pub3. 154. Islamoglu F, Ozcan K, Apaydin AZ, Soydas C, Bayindir O, Durmaz I. Diagnostic accuracy of N- terminal pro-brain natriuretic peptide in the evaluation of postoperative left ventricular diastolic dysfunction. Texas Heart Institute Journal. 2008; 35(2):111-118 155. Jaarsma T, Van Der Wal MH, Hogenhuis J, Lesman I, Luttik ML, Veeger NJ et al. Design and methodology of the COACH study: a multicenter randomised Coordinating study evaluating Outcomes of Advising and Counselling in Heart failure. European Journal of Heart Failure. 156. Jaarsma T, van der Wal MH, Lesman-Leegte I. Coordinating study evaluating outcomes of advising and counsenng in heart failure (COACH). ACC Cardiosource Review Journal. 2008; 157. Jaarsma T, van der Wal MH, Lesman-Leegte I, Luttik ML, Hogenhuis J, Veeger NJ et al. Effect of moderate or intensive disease management program on outcome in patients with heart failure: Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH). Archives of Internal Medicine. 2008; 168(3):316-24 158. Jaarsma T, van Veldhuisen DJ, van der Wal MH. NHF-COACH multicenter trial in The Netherlands: searching for underlying potentially beneficial mechanisms in nurse led heart failure management. Progress in Cardiovascular Nursing. 2002; 17(2):96-8 159. Januzzi JL, Jr., Rehman SU, Mohammed AA, Bhardwaj A, Barajas L, Barajas J et al. Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. Journal of the American College of Cardiology. 160. Joglar JA, Acusta AP, Shusterman NH, Ramaswamy K, Kowal RC, Barbera SJ et al. Effect of carvedilol on survival and hemodynamics in patients with atrial fibrillation and left ventricular dysfunction: retrospective analysis of the US Carvedilol Heart Failure Trials Program. American Heart Journal. 2001; 142(3):498-501 161. Joint Formulary Committee. British National Formulary. London. 2016. Available from: http://www.medicinescomplete.com 162. Jolicoeur EM, Dunning A, Castelvecchio S, Dabrowski R, Waclawiw MA, Petrie MC et al. Importance of angina in patients with coronary disease, heart failure, and left ventricular systolic dysfunction: insights from STICH. Journal of the American College of Cardiology. 163. Jourdain P, Jondeau G, Funck F, Gueffet P, Le Helloco A, Donal E et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. Journal of the American College of Cardiology. 2007; 49(16):1733-9 164. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. New England Journal of Medicine. 2004; 351(6):543-51 Chronic Heart Failure Reference list NICE 2018. All rights reserved. Subject to Notice of rights. ISBN: 978-1-4731-3093-7 165. Kanwar MK, Lohmueller LC, Kormos RL, Loghmanpour NA, Benza RL, Mentz RJ et al. Low accuracy of the HeartMate Risk Score for predicting mortality using the INTERMACS Registry data. ASAIO Journal. 2017; 63(3):251-256 166. Kao DP, Lewsey JD, Anand IS, Massie BM, Zile MR, Carson PE et al. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. European Journal of Heart Failure. 2015; 167. Kao DP, Wagner BD, Robertson AD, Bristow MR, Lowes BD. A personalized BEST: characterization of latent clinical classes of nonischemic heart failure that predict outcomes and response to bucindolol. PloS One. 2012; 7(11):e48184 168. Karapolat H, Demir E, Bozkaya YT, Eyigor S, Nalbantgil S, Durmaz B et al. Comparison of hospital-based versus home-based exercise training in patients with heart failure: effects on functional capacity, quality of life, psychological symptoms, and hemodynamic parameters. Clinical Research in Cardiology. 2009; 98(10):635-42 169. Karlstrom P, Alehagen U, Boman K, Dahlstrom U. Brain natriuretic peptide-guided treatment does not improve morbidity and mortality in extensively treated patients with chronic heart failure: responders to treatment have a significantly better outcome. European Journal of 170. Karlstrom P, Dahlstrom U, Boman K, Alehagen U. Responder to BNP-guided treatment in heart failure. The process of defining a responder. Scandinavian Cardiovascular Journal. 171. Karlstrom P, Johansson P, Dahlstrom U, Boman K, Alehagen U. Can BNP-guided therapy improve health-related quality of life, and do responders to BNP-guided heart failure treatment have improved health-related quality of life? Results from the UPSTEP study. BMC 172. Kaufmann BA, Goetschalckx K, Min SY, Maeder MT, Bucher U, Nietlispach F et al. Improvement in left ventricular ejection fraction and reverse remodeling in elderly heart failure patients on intense NT-proBNP-guided therapy. International Journal of Cardiology. 173. Kelder JC, Cramer MJ, Verweij WM, Grobbee DE, Hoes AW. Clinical utility of three B-type natriuretic peptide assays for the initial diagnostic assessment of new slow-onset heart failure. Journal of Cardiac Failure. 2011; 17(9):729-34 174. Ketchum ES, Jacobson AF, Caldwell JH, Senior R, Cerqueira MD, Thomas GS et al. Selective improvement in Seattle Heart Failure Model risk stratification using iodine-123 meta- iodobenzylguanidine imaging. Journal of Nuclear Cardiology. 2012; 19(5):1007-16 175. King's College London, NIHR HTA CET. REVascularisation for Ischaemic VEntricular Dysfunction (REVIVED). King's College London, NIHR HTA CET, 2013. Available from: 176. Klip IT, Comin-Colet J, Voors AA, Ponikowski P, Enjuanes C, Banasiak W et al. Iron deficiency in chronic heart failure: an international pooled analysis. American Heart Journal. 2013; 177. Knebel F, Eddicks S, Schimke I, Bierbaum M, Schattke S, Beling M et al. Myocardial tissue Doppler echocardiography and N-terminal B-type natriuretic peptide (NT-proBNP) in diastolic and systolic heart failure. Cardiovascular Ultrasound. 2008; 6:45 Chronic Heart Failure Reference list NICE 2018. All rights reserved. Subject to Notice of rights. ISBN: 978-1-4731-3093-7 178. Koehler F, Winkler S, Schieber M, Sechtem U, Stangl K, Bohm M et al. Impact of remote telemedical management on mortality and hospitalizations in ambulatory patients with chronic heart failure: the telemedical interventional monitoring in heart failure study. 179. Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet. 2009; 374(9704):1840-1848 180. Kotecha D, Flather MD, Altman DG, Holmes J, Rosano G, Wikstrand J et al. Heart Rate and Rhythm and the Benefit of Beta-Blockers in Patients With Heart Failure. Journal of the American College of Cardiology. 2017; 69(24):2885-2896 181. Kotecha D, Holmes J, Krum H, Altman DG, Manzano L, Cleland JG et al. Efficacy of beta blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta- 182. Kramer DB, Ottenberg AL, Gerhardson S, Mueller LA, Kaufman SR, Koenig BA et al. "Just because we can doesn't mean we should": views of nurses on deactivation of pacemakers and implantable cardioverter-defibrillators. Journal of Interventional Cardiac 183. Krum H, Forbes A, Yallop J, Driscoll A, Croucher J, Chan B et al. Telephone support to rural and remote patients with heart failure: the Chronic Heart Failure Assessment by Telephone (CHAT) study. Cardiovascular Therapeutics. 2013; 31(4):230-237 184. Krum H, Shi H, Pitt B, McMurray J, Swedberg K, Veldhuisen DJ et al. Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF study. Circulation: 185. Krupicka J, Janota T, Hradec J. Optimalization of heart failure therapy guided by plasma BNP concentrations. European Heart Journal. 2010; 31:859-860 186. Ky B, French B, Levy WC, Sweitzer NK, Fang JC, Wu AH et al. Multiple biomarkers for risk prediction in chronic heart failure. Circulation: Heart Failure. 2012; 5(2):183-90 187. LaDonna KA, Bates J, Tait GR, McDougall A, Schulz V, Lingard L. 'Who is on your health-care team?'Asking individuals with heart failure about care team membership and roles. Health 188. Lainchbury JG, Troughton RW, Frampton CM, Yandle TG, Hamid A, Nicholls MG et al. NT- proBNP-guided drug treatment for chronic heart failure: design and methods in the "BATTLESCARRED" trial. European Journal of Heart Failure. 2006; 8(5):532-8 189. Lainchbury JG, Troughton RW, Strangman KM, Frampton CM, Pilbrow A, Yandle TG et al. N- terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. Journal of the American College of Cardiology. 2009; 55(1):53- 190. Laramee AS, Levinsky SK, Sargent J, Ross R, Callas P. Case management in a heterogeneous congestive heart failure population: a randomized controlled trial. Archives of Internal Chronic Heart Failure Reference list NICE 2018. All rights reserved. Subject to Notice of rights. ISBN: 978-1-4731-3093-7 191. Laramee P, Wonderling D, Swain S, Al-Mohammad A, Mant J. Cost-effectiveness analysis of serial measurement of circulating natriuretic peptide concentration in chronic heart failure. 192. Lechat P, Hulot JS, Escolano S, Mallet A, Leizorovicz A, Werhlen-Grandjean M et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II 193. Ledwidge M, Barry M, Cahill J, Ryan E, Maurer B, Ryder M et al. Is multidisciplinary care of heart failure cost-beneficial when combined with optimal medical care? European Journal of 194. Lee D, Wilson K, Akehurst R, Cowie MR, Zannad F, Krum H et al. Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms. Heart. 2014; 195. Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA. 2003; 196. Lee MC, Sulmasy DP, Gallo J, Kub J, Hughes MT, Russell S et al. Decision-making of patients with implantable cardioverter-defibrillators at end of life: Family members experiences. American Journal of Hospice & Palliative Medicine. 2017; 34(6):518-523 197. Lesogor A, Cohn JN, Latini R, Tognoni G, Krum H, Massie B et al. Interaction between baseline and early worsening of renal function and efficacy of renin-angiotensin-aldosterone system blockade in patients with heart failure: insights from the Val-HeFT study. European Journal of 198. Levy WC, Mozaffarian D, Linker DT, Sutradhar SC, Anker SD, Cropp AB et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation. 2006; 113(11):1424-33 199. Lewis EF, Kim HY, Claggett B, Spertus J, Heitner JF, Assmann SF et al. Impact of spironolactone on longitudinal changes in health-related quality of life in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circulation: 200. Lewis GD, Malhotra R, Hernandez AF, McNulty SE, Smith A, Felker GM et al. Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency: The IRONOUT HF randomized clinical trial. JAMA. 2017; 317(19):1958- 201. Lim EA, Sohn HS, Lee H, Choi SE. Cost-utility of ferric carboxymaltose (Ferinject) for iron- deficiency anemia patients with chronic heart failure in South Korea. Cost Effectiveness & 202. Lord L, Dowswell G, Hewison A. The team for both sides? A qualitative study of change in heart failure services at three acute NHS Trusts. Health & Social Care in the Community. 203. Lubien E, DeMaria A, Krishnaswamy P, Clopton P, Koon J, Kazanegra R et al. Utility of B- natriuretic peptide in detecting diastolic dysfunction: Comparison with Doppler velocity 204. Lyng P, Persson H, H gg-Martinell A, H gglund E, Hagerman I, Langius-Ekl f A et al. Weight monitoring in patients with severe heart failure (WISH). A randomized controlled trial. European Journal of Heart Failure. 2012; 14(4):438-444 Chronic Heart Failure Reference list NICE 2018. All rights reserved. Subject to Notice of rights. ISBN: 978-1-4731-3093-7 205. Macdonald JE, Kennedy N, Struthers AD. Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment. Heart. 2004; 90(7):765-70 206. MacDonald MR, She L, Doenst T, Binkley PF, Rouleau JL, Tan RS et al. Clinical characteristics and outcomes of patients with and without diabetes in the Surgical Treatment for Ischemic Heart Failure (STICH) trial. European Journal of Heart Failure. 2015; 17(7):725-34 207. Macdonald S, Blane D, Browne S, Conway E, Macleod U, May C et al. Illness identity as an important component of candidacy: Contrasting experiences of help-seeking and access to care in cancer and heart disease. Social Science and Medicine. 2016; 168:101-110 208. MacIver J, Tibbles A, Billia F, Ross H. Patient perceptions of implantable cardioverter- defibrillator deactivation discussions: A qualitative study. SAGE Open Medicine. 2016; 209. MacKenzie E, Smith A, Angus N, Menzies S, Brulisauer F, Leslie SJ. Mixed-method exploratory study of general practitioner and nurse perceptions of a new community based nurse-led heart failure service. Rural & Remote Health. 2010; 10(4):1510 210. Maeder MT, Rickenbacher P, Rickli H, Abbuhl H, Gutmann M, Erne P et al. N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF). European Journal of Heart Failure. 211. Mallick A, Gandhi PU, Gaggin HK, Ibrahim N, Januzzi JL. The importance of worsening heart failure in ambulatory patients: Definition, characteristics, and effects of amino-terminal pro- b-type natriuretic peptide guided therapy. JACC Heart Failure. 2016; 4(9):749-55 212. Mant J, Doust J, Roalfe A, Barton P, Cowie MR, Glasziou P et al. Systematic review and individual patient data meta-analysis of diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care. Health Technology 213. Mark DB, Knight JD, Velazquez EJ, Wasilewski J, Howlett JG, Smith PK et al. Quality-of-life outcomes with coronary artery bypass graft surgery in ischemic left ventricular dysfunction: a randomized trial. Annals of Internal Medicine. 2014; 161(6):392-9 214. Martensson J, Stromberg A, Dahlstrom U, Karlsson JE, Fridlund B. Patients with heart failure in primary health care: effects of a nurse-led intervention on health-related quality of life and depression. European Journal of Heart Failure. 2005; 7(3):393-403 215. Massie BM, Armstrong PW, Cleland JG, Horowitz JD, Packer M, Poole-Wilson PA et al. Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. The Assessment of Treatment with Lisinopril and Survival. Archives of Internal Medicine. 2001; 161(2):165-71 216. May HT, Horne BD, Levy WC, Kfoury AG, Rasmusson KD, Linker DT et al. Validation of the Seattle Heart Failure Model in a community-based heart failure population and enhancement by adding B-type natriuretic peptide. American Journal of Cardiology. 2007; 217. McDonald K, Ledwidge M, Cahill J, Kelly J, Quigley P, Maurer B et al. Elimination of early rehospitalization in a randomized, controlled trial of multidisciplinary care in a high-risk, elderly heart failure population: the potential contributions of specialist care, clinical stability Chronic Heart Failure Reference list NICE 2018. All rights reserved. Subject to Notice of rights. ISBN: 978-1-4731-3093-7 and optimal angiotensin-converting enzyme inhibitor dose at discharge. European Journal of 218. McDonald K, Ledwidge M, Cahill J, Quigley P, Maurer B, Travers B et al. Heart failure management: multidisciplinary care has intrinsic benefit above the optimization of medical care. Journal of Cardiac Failure. 2002; 8(3):142-8 219. McLellan J, Heneghan CJ, Perera R, Clements AM, Glasziou PP, Kearley KE et al. B-type natriuretic peptide-guided treatment for heart failure. Cochrane Database of Systematic Reviews 2016, Issue 12. Art. No.: CD008966. DOI: 10.1002/14651858.CD008966.pub2. 220. Mejhert M, Kahan T, Persson H, Edner M. Limited long term effects of a management programme for heart failure. Heart. 2004; 90(9):1010-5 221. Merit-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999; 222. Moertl D, Berger R, Struck J, Gleiss A, Hammer A, Morgenthaler NG et al. Comparison of midregional pro-atrial and B-type natriuretic peptides in chronic heart failure: influencing factors, detection of left ventricular systolic dysfunction, and prediction of death. Journal of the American College of Cardiology. 2009; 53(19):1783-90 223. Moertl D, Steiner S, Coyle D, Berger R. Cost-utility analysis of NT-proBNP-guided multidisciplinary care in chronic heart failure. International Journal of Technology Assessment in Health Care. 2013; 29(1):3-11 224. Mohiuddin S, Reeves B, Pufulete M, Maishman R, Dayer M, Macleod J et al. Model-based cost-effectiveness analysis of B-type natriuretic peptide-guided care in patients with heart failure. BMJ Open. 2016; 6(12):e014010 225. Molloy GJ, Johnston DW, Witham MD. Family caregiving and congestive heart failure. Review and analysis. European Journal of Heart Failure. 2005; 7(4):592-603 226. Monahan M, Barton P, Taylor CJ, Roalfe A, Hobbs R. MICE or NICE? An Economic Evaluation of clinical decision rules in the diagnosis of Heart Failure in Primary Care. International Journal of Cardiology. 2017; 241:255-261 227. Morrison LJ, Calvin AO, Nora H, Porter Storey C. Managing cardiac devices near the end of life: A survey of hospice and palliative care providers. American Journal of Hospice & 228. Mortara A, Pinna GD, Johnson P, Maestri R, Capomolla S, La Rovere MT et al. Home telemonitoring in heart failure patients: the HHH study (Home or Hospital in Heart Failure). European Journal of Heart Failure. 2009; 11(3):312-8 229. Mueller PS, Ottenberg AL, Hayes DL, Koenig BA. "I felt like the angel of death": role conflicts and moral distress among allied professionals employed by the US cardiovascular implantable electronic device industry. Journal of Interventional Cardiac Electrophysiology. 230. Mulder BA, van Veldhuisen DJ, Crijns HJ, Bohm M, Cohen-Solal A, Babalis D et al. Effect of nebivolol on outcome in elderly patients with heart failure and atrial fibrillation: insights from SENIORS. European Journal of Heart Failure. 2012; 14(10):1171-8 Chronic Heart Failure Reference list NICE 2018. All rights reserved. Subject to Notice of rights. ISBN: 978-1-4731-3093-7 231. Murray SA, Boyd K, Kendall M, Worth A, Benton TF, Clausen H. Dying of lung cancer or cardiac failure: prospective qualitative interview study of patients and their carers in the 232. National Clinical Guideline Centre. Chronic heart failure: the management of chronic heart failure in adults in primary and secondary care. NICE clinical guideline 108. London. National Clinical Guideline Centre, 2010. Available from: http://guidance.nice.org.uk/CG108/ 233. National Clinical Guideline Centre. Patient experience in adult NHS services: improving the experience of care for people using adult NHS services. NICE clinical guideline 138. London. National Clinical Guideline Centre, 2012. Available from: http://www.nice.org.uk/CG138 234. National Clinical Guideline Centre. Acute heart failure: diagnosing and managing acute heart failure in adults. NICE clinical guideline 187. London. National Clinical Guideline Centre, 2014. Available from: http://guidance.nice.org.uk/CG187 235. National Institute for Cardiovascular Outcomes Research (NICOR), Institute of Cardiovascular Science. National heart failure audit. London. 2017. Available from: http://www.ucl.ac.uk/nicor/audits/heartfailure/reports 236. National Institute for Health and Care Excellence. Developing NICE guidelines: the manual. London. National Institute for Health and Care Excellence, 2014. Available from: 237. National Institute for Health and Clinical Excellence. Social value judgements: principles for the development of NICE guidance. London. National Institute for Health and Clinical Excellence, 2008. Available from: https://www.nice.org.uk/media/default/about/what-we- do/research-and-development/social-value-judgements-principles-for-the-development-of- nice-guidance.pdf 238. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal 2013. London. National Institute for Health and Clinical Excellence, 2013. Available 239. NHS Business Services Authority. NHS electronic drug tariff, May 2017. 2015. Available from: http://www.nhsbsa.nhs.uk/PrescriptionServices/4940.aspx Last accessed: 06/12/18. 240. NHS Business Services Authority. NHS electronic drug tariff May 2016. 2016. Available from: https://www.nhsbsa.nhs.uk/pharmacies-gp-practices-and-appliance-contractors/drug-tariff Last accessed: 27/11/2017. 241. NHS Commissioning Assembly. Technology enabled care services : resource for commissioners. 2015. Available from: https://www.england.nhs.uk/wp- 242. NHS England. Reference costs 2014- 15. Department of Health, 2015. Available from: 243. Nielsen LS, Svanegaard J, Klitgaard NA, Egeblad H. N-terminal pro-brain natriuretic peptide for discriminating between cardiac and non-cardiac dyspnoea. European Journal of Heart 244. Nucifora G, Albanese MC, De Biaggio P, Caliandro D, Gregori D, Goss P et al. Lack of improvement of clinical outcomes by a low-cost, hospital-based heart failure management programme. Journal of Cardiovascular Medicine. 2006; 7(8):614-22 Chronic Heart Failure Reference list NICE 2018. All rights reserved. Subject to Notice of rights. ISBN: 978-1-4731-3093-7 245. O'Shea P, Daly R, Kasim S, Tormey WP. B-type natriuretic peptide in the cardiology department. Irish Medical Journal. 2012; 105(10):341-3 246. Ojeda S, Anguita M, Delgado M, Atienza F, Rus C, Granados AL et al. Short- and long-term results of a programme for the prevention of readmissions and mortality in patients with heart failure: are effects maintained after stopping the programme? European Journal of 247. Ong MK, Romano PS, Edgington S, Aronow HU, Auerbach AD, Black JT et al. Effectiveness of remote patient monitoring after discharge of hospitalized patients with heart failure the better effectiveness after transition-heart failure (BEAT-HF) randomized clinical trial. JAMA 248. Ordonez-Llanos J, Collinson PO, Christenson RH. Amino-terminal pro-B-type natriuretic peptide: analytic considerations. American Journal of Cardiology. 2008; 101(3a):9-15 249. Organisation for Economic Co-operation and Development (OECD). Purchasing power parities (PPP). Available from: http://www.oecd.org/std/prices-ppp/ Last accessed: 06/12/2017. 250. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. New England Journal of Medicine. 1996; 334(21):1349-55 251. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P et al. Effect of carvedilol on survival in severe chronic heart failure. New England Journal of Medicine. 2001; 252. Pandor A, Thokala P, Gomersall T, Baalbaki H, Stevens J, Wang J et al. Home telemonitoring or structured telephone support programmes after recent discharge in patients with heart failure: systematic review and economic evaluation. Health Technology Assessment. 2013; 253. Panza JA, Holly TA, Asch FM, She L, Pellikka PA, Velazquez EJ et al. Inducible myocardial ischemia and outcomes in patients with coronary artery disease and left ventricular dysfunction. Journal of the American College of Cardiology. 2013; 61(18):1860-70 254. Panza JA, Velazquez EJ, She L, Smith PK, Nicolau JC, Favaloro RR et al. Extent of coronary and myocardial disease and benefit from surgical revascularization in ischemic LV dysfunction. Journal of the American College of Cardiology. 2014; 64(6):553-61 255. Paterson I, Wells GA, Ezekowitz JA, White JA, Friedrich MG, Mielniczuk LM et al. Routine versus selective cardiac magnetic resonance in non-ischemic heart failure - OUTSMART-HF: study protocol for a randomized controlled trial (IMAGE-HF (heart failure) project 1-B). Trials. 256. Persson H, Erntell H, Eriksson B, Johansson G, Swedberg K, Dahlstrom U. Improved pharmacological therapy of chronic heart failure in primary care: a randomized Study of NT- proBNP Guided Management of Heart Failure SIGNAL-HF (Swedish Intervention study Guidelines and NT-proBNP AnaLysis in Heart Failure). European Journal of Heart Failure. 257. Peters-Klimm F, Campbell S, Hermann K, Kunz CU, Muller-Tasch T, Szecsenyi J. Case management for patients with chronic systolic heart failure in primary care: The HICMan exploratory randomised controlled trial. Trials. 2010; 11 56 Chronic Heart Failure Reference list NICE 2018. All rights reserved. Subject to Notice of rights. ISBN: 978-1-4731-3093-7 258. Peters-Klimm F, Muller-Tasch T, Schellberg D, Gensichen J, Muth C, Herzog W et al. Rationale, design and conduct of a randomised controlled trial evaluating a primary care-based complex intervention to improve the quality of life of heart failure patients: HICMan (Heidelberg Integrated Case Management). BMC Cardiovascular Disorders. 2007; 7:25 259. Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation. 2015; 131(1):34-42 260. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM- Overall programme. Lancet. 2003; 362(9386):759-66 261. Pfisterer M, Buser P, Rickli H, Gutmann M, Erne P, Rickenbacher P et al. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA. 2009; 262. Piotrowicz E, Baranowski R, Bilinska M, Stepnowska M, Piotrowska M, Wojcik A et al. A new model of home-based telemonitored cardiac rehabilitation in patients with heart failure: effectiveness, quality of life, and adherence. European Journal of Heart Failure. 2010; 263. Piotrowicz E, Stepnowska M, Leszczynska-Iwanicka K, Piotrowska D, Kowalska M, Tylka J et al. Quality of life in heart failure patients undergoing home-based telerehabilitation versus outpatient rehabilitation a randomized controlled study. European Journal of Cardiovascular 264. Pitt B, Gheorghiade M, Zannad F, Anderson JL, Van V, Parkhomenko A et al. Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction less-than or equal to 30%. European Journal of Heart Failure. 2006; 8(3):295-301 265. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B et al. Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine. 2014; 266. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. New England Journal of Medicine. 2003; 348(14):1309-1321 267. Pitt B, White H, Nicolau J, Martinez F, Gheorghiade M, Aschermann M et al. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. Journal of the American College of Cardiology. 2005; 46(3):425-431 268. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. New England Journal of Medicine. 1999; 341(10):709-717 269. Ponikowski P, Filippatos G, Colet JC, Willenheimer R, Dickstein K, Luscher T et al. The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study. 